Assessment of Clinical and Economic Effectiveness of Alectinib for Patients With ALK+ Non-Small Cell Lung Cancer Without Previous Experience of Targeted Therapy
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
doi 10.31556/2219-0678.2019.38.4.087-100
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Fund Gelios